Antisense Therapeutics
(ASX:ANP)
Our Latest Articles on Antisense Therapeutics
| Type | Date | Title |
|---|---|---|
| Article | 19-Dec-2019 | ANP to Rapidly Advance to Phase IIb Trial After Dosing Results Exceed Expectations |
Market Data
Latest Article
ANP to Rapidly Advance to Phase IIb Trial After Dosing Results Exceed Expectations
Dec 19, 2019
One ASX biotech that is making progress in DMD therapy and hoping to shake up an industry set to be worth US$4 billion by 2023 is Antisense Therapeutics (ASX:ANP).
Related Articles
ASX Junior’s Flagship Immunomodulatory Drug Could Turn the Tide in Duchenne Muscular Dystrophy Treatment
Oct 16, 2018
Duchenne muscular dystrophy (DMD) is a rare, yet fatal, muscular genetic condition that affects one in 3600 to 6000 male births worldwide. This ASX junior, capped at just $7 million, is already in a Phase II clinical trial with its flagship drug to treat DMD.
